University of Magdeburg
Welcome,         Profile    Billing    Logout  
 13 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ricke, Jens
NCT04238637 / 2018-004778-81: Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Recruiting
2
50
Europe
Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca
Intrahepatic Cholangiocarcinoma
12/25
12/25
HOMIE-166, NCT05451862: Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

Recruiting
2
73
Europe
Holmium-166 treatment, QuiremSpheresTM Holmium-166 Microspheres, Holmium-166 work-up, QuiremScoutTM Holmium-166 Microspheres
Terumo Europe N.V.
Hepatocellular Carcinoma
01/31
01/31
Koenigsmann, Michael
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
Schostak, Martin
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
OPTIMUM, NCT05220501: Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

Completed
N/A
804
Europe, Canada, US
Micro-US Targeted Biopsy, MRI Targeted Biopsy
Sunnybrook Health Sciences Centre, Exact Imaging
Prostate Cancer
09/24
11/24

Download Options